Ariella Pharmaceuticals
A
About Ariella
Who we are
We are a research-driven, pharmaceutical company dedicated to finding a cure for neurodegenerative disorders using nucleic acid therapy.
Founded by Dr. Lewis Smith and Dr. Jane Joes in 2015, we are always striving to be at the forefront of research and development, and we work tirelessly to advance the field of nucleic acid therapy in neurodegenerative disorders, including Huntington's disease and Alzheimer's disease.
Our teams are committed to using the latest advancements in technology and science to develop innovative treatments that will make a difference in people's lives.
Dr. Jane Joes
Co-Founder and CEO
Dr. Lewis Smith
Co-Founder and Chief Scientist
Our Mission
To reinvent the future of pharmaceutics through delivering cutting-edge treatments that transform lives.
Our vision and values
Our vision is to be the industry-leading company that discovers, invents, and delivers transformative nucleic acid therapy for patients with neurodegenerative disorders.
At Ariella Pharmaceuticals, we put the patients' needs above our own and strive to deliver high-quality treatments for unknown disease-modifying interventions that generally require a long research and development (R&D) cycle.
​
3 Main Values
Innovative
Focus on our creative thinking by pushing the boundaries of debilitating diseases and developing new-era treatments.
Inclusive
We are comprised of people with diverse backgrounds and thoughts, bringing their expertise and new insights to work.
Sustainability
We consider environmental, social, and governance (ESG) when making sustainable choices in operations and research.
Our story: current stage, and the next step
In 2023, we will have developed the world's first nucleic acid drug, Nominsen®, for Huntington's disease, completed our Phase III clinical trials, and published our data, showcasing its promising safety and efficacy in treating the disease. To date, Nominsen® is expected to receive FDA and MHRA approval in the US and UK and is planned to be on the market in June 2024.
Beyond the success of Nominsen®, we are starting our development on a novel drug that specifically targets the remaining population, which could cover more than 70% of the affected population around the world. ​
